Venus Remedies gets additional US patent nod for Vancoplus
May 26 2014 , New Delhi
"Venus Remedies already has product patent for Vancoplus from USPTO. This additional patent with broader coverage for use and method of treatment will be beneficial for the company," Venus Remedies said in a filing to BSE.
The patent is valid till 2032 and the company has already initiated pre-Investigational New Drug meeting with US health regulator, it added.
Vancoplus is a highly effective remedy to control Methicillin-resistant Staphylococcus aureus (MRSA), VRSA (Vancomycin Resistance Staphylococcus aureus) and other bacterial infections.
Global anti-bacterial market is slated to reach around USD 64 billion by 2018, Venus Remedies said.
Shares of Venus Remedies were trading at Rs 302.80 per scrip in the afternoon trade on BSE, up 0.26 per cent from its previous close.